FDA says Abraxis failed to proactively address repeat media fill contamination issues

Regulatory NewsRegulatory NewsBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy